NCT00386321View on ClinicalTrials.gov

Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

January 31, 2010

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)

Trial Locations (1)

10330

King Chulalongkorn Memorial Hospital, Bangkok

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Chulalongkorn University

OTHER